Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.67 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6884411 | 0.94 | PTGS1 (0.60) | PTGS1AKR1C3AKR1C2KDM4ENPC1 | |
| SCHEMBL27767912 | 0.88 | PTGS1 (0.63) | PTGS1AKR1C3AKR1C2KDM4ENPC1 | |
| SCHEMBL25968365 | 0.88 | PTGS1 (0.67) | PTGS1AKR1C3AKR1C2KDM4ENPC1 | |
| SCHEMBL1448732 | 0.85 | PTGS1 (0.73) | PTGS1AKR1C3AKR1C2KDM4ENPC1 | |
| SCHEMBL924496 | 0.85 | KMT2A (0.63) | CYP3A4MEN1KMT2AALDH1A1HTT | |
| SCHEMBL22959838 | 0.85 | PTGS1 (0.63) | PTGS1AKR1C3AKR1C2KDM4ENPC1 | |
| SCHEMBL12946405 | 0.85 | MAPT (0.68) | PTGS1AKR1C3AKR1C2KDM4ENPC1 | |
| SCHEMBL6884586 | 0.85 | PTGS1 (0.63) | PTGS1AKR1C3AKR1C2KDM4ENPC1 | |
| SCHEMBL6886141 | 0.85 | PTGS1 (0.72) | PTGS1AKR1C3AKR1C2KDM4ENPC1 | |
| SCHEMBL7419945 | 0.84 | MAOB (0.49) | PTGS1AKR1C3AKR1C2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3737663-B1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | UNIV COURT UNIV ST ANDREWS (GB) | 2023-02-22 | — | — | EP | disclosed |
| CN-113308704-B | Electrooxidation preparation method of naproxen intermediate | 湖南大学 | 2022-04-08 | — | — | CN | disclosed |
| CN-113308704-A | Electrooxidation preparation method of naproxen intermediate | 湖南大学 | 2021-08-27 | — | — | CN | disclosed |
| EP-2291358-B1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2291358-B1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME (US) | 2018-03-28 | — | — | EP | disclosed |
| US-8623818-B2 | Glucagon receptor antagonists, compositions, and methods for their use | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20110065634-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| EP-2291358-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | Schering Corporation (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009140342-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | SCHERING CORPORATION (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2008141033-A1 | SUBSTITUTED NAPHTHALENES | AUSPEX PHARMACEUTICALS INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-4207241-A | ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS AND ANTIPRURITIC AGENTS | SYNTEX CORPORATION (US) | 1980-06-10 | — | — | US | disclosed |
| US-4097674-A | ANTIINFLAMMATORY, ANTIPYRETIC, ANTIPRURITIC AGENTS, ANALGESICS | SYNTEX CORPORATION (US) | 1978-06-27 | — | — | US | disclosed |
| US-4051233-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (US) | 1977-09-27 | — | — | US | disclosed |
| US-4048330-A | Compositions containing 2-(6'-substituted-2'-naphthyl)acetic acid esters used for treating inflammation, pain or pyrexia | SYNTEX CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-4009197-A | 2-(6-Substituted-2'-naphthyl) acetic acid derivatives and the salts and esters thereof | SYNTEX CORPORATION (PM) | 1977-02-22 | — | — | US | disclosed |
| US-4001301-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS, ANTI-PRURITIC | SYNTEX CORPORATION (PM) | 1977-01-04 | — | — | US | disclosed |
| US-3998966-A | Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof | SYNTEX CORPORATION (PM) | 1976-12-21 | — | — | US | disclosed |
| US-3980699-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (PM) | 1976-09-14 | — | — | US | disclosed |
| US-3978116-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
| US-3978124-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065634-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | PTGS1 705/4885AKR1C3 223/4885AKR1C2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.